Beam Therapeutics (Beam Therapeutics) Forward Dividend Yield % : 0.00% (As of Apr. 29, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Beam Therapeutics Forward Dividend Yield %?

As of today (2024-04-29), the Forward Annual Dividend Yield of Beam Therapeutics is 0.00%.

As of today (2024-04-29), the Trailing Annual Dividend Yield of Beam Therapeutics is 0.00%.

BEAM's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.475
* Ranked among companies with meaningful Forward Dividend Yield % only.

Beam Therapeutics's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Beam Therapeutics's Forward Dividend Yield %

For the Biotechnology subindustry, Beam Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beam Therapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Beam Therapeutics's Forward Dividend Yield % falls into.

Beam Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Beam Therapeutics (NAS:BEAM) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Beam Therapeutics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Beam Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Beam Therapeutics (Beam Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beam Therapeutics Inc (NAS:BEAM) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

BEAM:Mexico

Address

238 Main Street, Cambridge, MA, USA, 02142

Website

https://www.beamtx.com

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.

Executives

Christine Bellon	officer: Chief Legal Officer	BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142
Amy Simon	officer: Chief Medical Officer	BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142
Giuseppe Ciaramella	officer: President & CSO	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
John M. Evans	director, officer: CEO	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Terry-ann Burrell	officer: CFO	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Fmr Llc	10 percent owner, other: See Remark 1	245 SUMMER STREET, BOSTON MA 02210
John Maraganore	director	75 SIDNEY ST, CAMBRIDGE MA 02139
Graham K Cooper	director	C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Kathleen E Walsh	director	C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Arch Venture Fund Ix Overage, L.p.	10 percent owner	8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Stephen C Knight	director	C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Mark Fishman	director	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Arch Venture Partners Ix, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Ix, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Ix Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631